Menu
Recruiting NCT04697823

Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate.

No phase Interventional Hyaluronan-EnRiched Medium Randomized Controlled Trial

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: use of hyaluronan-enriched transfer medium.
Who it may be relevant to
Registry conditions: Hyaluronan-EnRiched Medium, Randomized Controlled Trial. Basic parameters: 18 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Belgium
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate: a Prospective Randomized Trial

Overview

Assessing whether the use of hyaluronan-enriched transfer medium can increase the cumulative ongoing pregnancy rate

Interventions

  • Other use of hyaluronan-enriched transfer medium
    In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium

Primary outcome measures

  • number of transfers needed to reach ongoing pregnancy [Time frame: ongoing defined as a pregancy with a viable fetus with FHB at 12 weeks of pregnancy]
Secondary outcome measures (1)
  • number of transfers needed to reach clinical pregnancy, life birth, miscarriage, multiple pregnancy [Time frame: until Live birth: 9 months after ET]

Eligibility criteria

Inclusion criteria

  • Patients with own oocytes/embryos;
  • Patients with female age at 1st OR in the study <40 year;
  • Patients planned for a 2nd oocyte retrieval, with no clinical ongoing pregnancy after the previous oocyte retrieval
  • Patients planned for a 3rd oocyte retrieval with no clinical ongoing pregnancy after previous oocyte retrievals
  • Patients with female age at 1st OR in the study <40 year;
  • Patients with BMI ≤32;
  • Patients with written informed consent;

Exclusion criteria

\-

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Belgium · 1 center
  • Leuven University Fertility Center — Leuven

Identifiers

NCT: NCT04697823 · S64387

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗